Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Evans Elizabeth E.

2. Date of Event Requiring Statement (MM/DD/YYYY) 5/11/2021

3. Issuer Name and Ticker or Trading Symbol

VACCINEX, INC. [VCNX]

(Last) (First) (Middle)

C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Operating Officer /

(Street)

ROCHESTER, NY 14620

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9600	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	12/22/2025	Common Stock	9610	$7.1	D
Stock Option (Right to Buy)	⁽¹⁾	12/23/2025	Common Stock	8605	$7.1	D
Stock Option (Right to Buy)	⁽²⁾	3/14/2029	Common Stock	12400	$3.9	D
Stock Option (Right to Buy)	⁽³⁾	4/4/2030	Common Stock	10000	$3.82	D
Stock Option (Right to Buy)	⁽⁴⁾	4/3/2031	Common Stock	8000	$2.93	D

Explanation of Responses:
(1)	This option is fully exercisable as of the date of this report
(2)	This option has vested with respect to 6,200 shares and the remainder vests in two equal annual installments beginning on March 15, 2022.
(3)	This option has vested with respect to 2,500 shares and the remainder vests in three equal annual installments beginning on April 3, 2022.
(4)	This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Evans Elizabeth E. C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE ROCHESTER, NY 14620			Chief Operating Officer